Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Please go back and re-read my opening sentence.
Nothing about Delcath's drug portfolio has changed since this article was written. Nothing.
In fact, with the strong interim safety analysis report and FDA's willingness to reduce thresholds to have more patience join Phase 3 of the FOCUS trial, DCTH's drug portfolio is in a better position since the article, IMO.
That is the expectation unless they got over 8.5 different buyers purchasing under 21M shares each. We'll know more over the next 24-48 hours, IMO.
Good luck.
Good morning all. I look forward to some good dialogue and some green this week!
GLTYA.
Lol. So true. So sad.
So now that you’ve sold we won’t see you posting for awhile I guess.
Good luck and happy trading.
YAWN.
Goodnight, Sam.
Trends.google.com.
Plug in DCTH.
Search.
Sure has a huge following in Canada for some reason.
Tick Tock.
Haha. Three billion shares. That’s a hoot!
I think I’ll side with institutional investors who paid $4.5M for 230M shares at $.02 two weeks ago over your assessment of less than $.01 per share.
Too bad you sold. She closes up and green by Friday.
Question: how is your fair assessment at below $.o1 when 230M shares were just sold for twice that less than two weeks ago?
I have no plans for Romania!
I have every confidence in securing a royal title with proceeds from the sale of some of my DCTH holdings. Once we start heading north, I’ll provide additional detail. Right now I am thinking Coburg or Liechtenstein.
I hope H20 decides to join. Either way, it sure beats the heck out of becoming a castrato...a reality closer now given the current PPS.
I think we’ve reached bottom. I am looking forward to see who purchased the remaining 180M shares as part of the private placement.
I will not be dismayed if the buyer turns out to be HB, or a combo of institutional investors. After all, this go round of financing, DCTH got paid $.02 per share rather than getting crushed by toxic financing.
Baby steps.
Now if it’s someone like ATNX, all the better.
Either way, it’s still a win-win for DCTH.
Reversal in the works, IMO.
Nothing about Delcath's drug portfolio has changed since this article was written. Nothing.
Delcath Systems Offers Significant Upside For Risk-Tolerant Investors
Jul.10.17 | About: Delcath Systems, (DCTH)
Jesse Donovan
Delcath Systems is developing unique, proprietary medical products which are aimed at treating the unmet needs of patients with liver cancer.
There has been significant regulatory and commercial progress in Europe as well as substantial clinical trial progress in the United States.
Recently released clinical data has provided shareholders with renewed optimism.
Significant potential upside awaits investors who are willing to tolerate the risk associated with this investment.
Delcath Systems (DCTH) offers tremendous potential upside for investors who are willing to tolerate a high degree of risk. Shareholders stand to reap a financial windfall if the company manages to successfully navigate clinical, regulatory, and financial hurdles. Delcath Systems' rock-bottom share price provides investors with the opportunity to initiate a large position in the company and take advantage of this uniquely asymmetric risk/reward opportunity.
https://seekingalpha.com/article/4086621-delcath-systems-offers-significant-upside-risk-tolerant-investors
I wonder if we’re in for some good earnings news like we received last last quarter.
Delcath Announces Third Quarter 2017 Financial Results
Highlights from the third quarter of 2017 and recent weeks include:
· Revenue for the third quarter of 2017 increased 75% to $0.7 million from $0.4 million in the prior-year quarter;
· Revenue for the first nine months of 2017 increased 53% to $2.0 million from $1.3 million in the prior-year period;
· Medical University of Hannover achieved its 100th CHEMOSAT treatment milestone; over 450 commercial CHEMOSAT procedures have been performed in Europe;
· Positive results from a single institution study of CHEMOSAT filtration efficiency were presented at 2017 CIRSE annual meeting in September
http://delcath.com/reuters-news/?id=2317164
Ecrypt One is a joke. Download it and set it up yourself. I did when it was selling on Amazon. In fact, I think it’s STILL on sale...two years later, on sale and not even a single sale. At least according to the filings.
I urge you, download it. It’s junk. You’ll see.
Where is the healthcare company purchase of the software? Where is the poop your pants news? Where are the contracts for the 5 ECRYPT ONE sales announced in 2015-2016. Oh that’s right, Tom went dark on filings for almost two years hoping people would forget that, AND Viking telecom...
Tom is Lord of the Clowder, and he’s got a wicked laser pointer.
When Trump talks swamp people, he’s talking about people like oochie goochie Cellucci. Using prior DC connections and his credentials to advance himself and no one else, IMO.
I’m not worried money, my friend. I just find it tiresome responding to the baseless drivel that’s been posted lately.
I supposed I could be like you, who is a shareholder one day then just “holding cash” the next (eyes rolling).
The PPS will speak for itself soon enough.
Have a nice weekend.
They can’t answer because they don’t know. But what they will do is conjure a date which casts the most negative light on DCTH, as always.
GLTYA
I don’t presume to know why people like you and Turntheship are so negative and unpleasant, I really don’t. I don’t know if you are paid, because absent having a vested interest in DCTH in some form or another, it makes no sense to post as much as you.
You root for failure. For misery and for people to lose money. It’s sad.
But I don’t have to subject myself to it anymore. You sir, are on my ignore list.
Buhbye
Oh well, welcome to ignore.
Should have known. You opened a free account on 2/18/2018. 4 negative posts on DCTH.
LoL, you boys need to step up your game.
Buhbye.
It don’t pump, I buy when I say I buy.
And yeah, the near term catalyst of the interim safety analysis report didn’t pan out like I expected. Oh well, that’s called life.
I said it then and I’ll say it again, I’m playing the long game. Would you like me to PM you as well, so you have a copy for the record and won’t have to bother me again?
Welcome to ignore.
On Delcath’s 500th Commercial CHEMOSAT Treatment in Europe:
This is a meaningful milestone for Delcath, one that speaks to the belief physicians in Europe have developed in our product and this therapy for certain types of liver cancers. Our commercialization efforts in Europe have established a considerable body of published and presented research data that demonstrates the safety and efficacy of this therapy in appropriate patients. Further, Dutch Health Authorities recently included CHEMOSAT treatment in their published guidelines for ocular melanoma liver metastases, a step toward potential reimbursement coverage of CHEMOSAT in the Dutch market. We continue to leverage this experience to validate the safety and efficacy of the melphalan/Hepatic Delivery System (CHEMOSAT) in our clinical trials.”
http://delcath.com/reuters-news/?id=2330074
Delcath Announces Preliminary Safety Analysis for Phase 3 Focus Trial
“The DSMB’s recommendation to proceed without modification with the FOCUS Trial as planned confirms our own observations of the safety profile of PHP therapy based on prior research and our commercial experience with CHEMOSAT in Europe,” said Jennifer K. Simpson, Ph.D., MSN, CRNP President and CEO of Delcath. “Importantly, this initial independent evaluation of the safety profile of melphalan/HDS used the Generation Two filter configuration of the device and the current version of the procedure protocol, and so provides confidence in both our product and procedure. Given that safety concerns with the previous generation product and procedure were the primary issue in the FDA’s previous assessment, we are pleased to have successfully passed this important milestone.
http://delcath.com/reuters-news/?id=2323336
Good point. Let’s go with: “this is the time, this is the place.”
Have a good weekend.
It’s not the revenue, Sam. It’s the data.
Tell me you understand the value of the safety and efficacy of the CHEMSAT 2.0 treatments are far more valuable than the revenue at this point in the game.
YAWN.
Now, you may clock out. I won’t be back until Monday.
Auf Wiedersehen.
Your pearl clutching makes me chuckle, Herr Trompete.
Play the long game and this is a no brainer. And while I do feel for those who got the dagger in years past, I will say this:
It is a mathematical certainty DCTH will get FDA approval for CHEMSAT 2.0.
And in the current political environment, access this protocol—driven by ‘Right To Try’ (or through direct negotiation with the FDA—may come much sooner than 2019.
With FDA approval comes American insurance with payments in 30-45 days, not the ghastly Euro foot dragging insurance reimbursements.
Shortly thereafter comes the expanded application of CHEMSAT 2.0 to other forms of cancer of the liver and colon (a $2.5 billion market annually).
But beyond the back and forth bickering, understand one thing: I would gladly forfeit my entire investment in DCTH if a cure could be found tomorrow. This vile disease has taken some very close people from me.
So forgive me when I chuckle reading your penny ante posts, and those like you who have come and gone, and sadly, for those who will come after you are gone.
Nothing about Delcath's drug portfolio has changed since this article was written. Nothing.
Delcath Systems Offers Significant Upside For Risk-Tolerant Investors
Jul.10.17 | About: Delcath Systems, (DCTH)
Jesse Donovan
Delcath Systems is developing unique, proprietary medical products which are aimed at treating the unmet needs of patients with liver cancer.
There has been significant regulatory and commercial progress in Europe as well as substantial clinical trial progress in the United States.
Recently released clinical data has provided shareholders with renewed optimism.
Significant potential upside awaits investors who are willing to tolerate the risk associated with this investment.
Delcath Systems (DCTH) offers tremendous potential upside for investors who are willing to tolerate a high degree of risk. Shareholders stand to reap a financial windfall if the company manages to successfully navigate clinical, regulatory, and financial hurdles. Delcath Systems' rock-bottom share price provides investors with the opportunity to initiate a large position in the company and take advantage of this uniquely asymmetric risk/reward opportunity.
https://seekingalpha.com/article/4086621-delcath-systems-offers-significant-upside-risk-tolerant-investors
Hopefully, we'll get an ownership update today after the close or on Monday.
SimSim, this is the only troubling thing I want an answer for:
PROPOSAL 1: INCREASE IN AUTHORIZED SHARES
Background of the Authorized Share Increase Proposal
Our Board has determined that it is advisable and in our and our stockholders’ best interests to increase the number of authorized shares of common stock from 500,000,000 to 1,000,000,000 shares, par value $0.01 per share. Accordingly, stockholders are asked to approve an amendment to our Articles of Incorporation to effectuate such increase.
The Board strongly believes that the increase in the number of authorized shares of common stock is necessary to provide us with sufficient authorized shares so that the holders of the Series D warrants issued in conjunction with our February 9, 2018 public offering may exercise their warrants.
So what happens if the vote is no? Seems pretty reckless for both parties to contract for a future event that may or may not happen as part of a present day bargain.
http://phx.corporate-ir.net/phoenix.zhtml?c=123840&p=irol-SECText&TEXT=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTEyMDU4NjU0JkRTRVE9MCZTRVE9MCZTUURFU0M9U0VDVElPTl9FTlRJUkUmc3Vic2lkPTU3#tx490723_1
Delcath Announces Preliminary Safety Analysis for Phase 3 Focus Trial
“The DSMB’s recommendation to proceed without modification with the FOCUS Trial as planned confirms our own observations of the safety profile of PHP therapy based on prior research and our commercial experience with CHEMOSAT in Europe,” said Jennifer K. Simpson, Ph.D., MSN, CRNP President and CEO of Delcath. “Importantly, this initial independent evaluation of the safety profile of melphalan/HDS used the Generation Two filter configuration of the device and the current version of the procedure protocol, and so provides confidence in both our product and procedure. Given that safety concerns with the previous generation product and procedure were the primary issue in the FDA’s previous assessment, we are pleased to have successfully passed this important milestone.
http://delcath.com/reuters-news/?id=2323336
Positive Results From a Multi-Center Analysis of Delcath PHP Therapy Published in Journal of Surgical Oncology
The study authors further concluded that “results clearly demonstrate that PHP Therapy appears to be an effective means of obtaining rapid intrahepatic disease control, and is a sensible option in patients with predominant liver disease.” Researchers said their results support the use of PHP Therapy in an integrated approach to the management of metastatic ocular melanoma, and looked to the company’s Phase 3 FOCUS Trial to further quantify the benefit and optimize treatment strategies for these patients.
https://www.otcmarkets.com/stock/DCTH/news/Positive-Results-From-a-Multi-Center-Analysis-of-Delcath-PHP-Therapy-Published-in-Journal-of-Surgical-Oncology?id=179899
Trump presses key Republican to move on ‘right to try’
https://www.statnews.com/2018/02/14/trump-walden-right-to-try/
On Delcath’s 500th Commercial CHEMOSAT Treatment in Europe:
This is a meaningful milestone for Delcath, one that speaks to the belief physicians in Europe have developed in our product and this therapy for certain types of liver cancers. Our commercialization efforts in Europe have established a considerable body of published and presented research data that demonstrates the safety and efficacy of this therapy in appropriate patients. Further, Dutch Health Authorities recently included CHEMOSAT treatment in their published guidelines for ocular melanoma liver metastases, a step toward potential reimbursement coverage of CHEMOSAT in the Dutch market. We continue to leverage this experience to validate the safety and efficacy of the melphalan/Hepatic Delivery System (CHEMOSAT) in our clinical trials.”
http://delcath.com/reuters-news/?id=2330074
auf wiedersehen!
Nothing about Delcath's drug portfolio has changed since this article was written. Nothing.
Delcath Systems Offers Significant Upside For Risk-Tolerant Investors
Jul.10.17 | About: Delcath Systems, (DCTH)
Jesse Donovan
Delcath Systems is developing unique, proprietary medical products which are aimed at treating the unmet needs of patients with liver cancer.
There has been significant regulatory and commercial progress in Europe as well as substantial clinical trial progress in the United States.
Recently released clinical data has provided shareholders with renewed optimism.
Significant potential upside awaits investors who are willing to tolerate the risk associated with this investment.
Delcath Systems (DCTH) offers tremendous potential upside for investors who are willing to tolerate a high degree of risk. Shareholders stand to reap a financial windfall if the company manages to successfully navigate clinical, regulatory, and financial hurdles. Delcath Systems' rock-bottom share price provides investors with the opportunity to initiate a large position in the company and take advantage of this uniquely asymmetric risk/reward opportunity.
https://seekingalpha.com/article/4086621-delcath-systems-offers-significant-upside-risk-tolerant-investors
I don’t think he’s clocked in yet.
Sorry my friend. Just getting annoyed at the jackwads MAXM and CDEL sitting on the ask and snuffing out any organic move north.
I was willing to endure it during the ghastly conversion but after the PR indicating it was essentially done, and given the leak outs for the mysterio buyer (if there is one) and Ayerton can’t sell until April, where are these shares coming from?
I send about 10 emails a week. I get a response about every 18th.
I have 4 in so far this week. Nothing.
It’s about holding the company accountable. Try multiple emails, they will eventually answer.
If someone could pose the question about the patents to IR and report back here, that would be great.
Positive Results From a Multi-Center Analysis of Delcath PHP Therapy Published in Journal of Surgical Oncology
The study authors further concluded that “results clearly demonstrate that PHP Therapy appears to be an effective means of obtaining rapid intrahepatic disease control, and is a sensible option in patients with predominant liver disease.” Researchers said their results support the use of PHP Therapy in an integrated approach to the management of metastatic ocular melanoma, and looked to the company’s Phase 3 FOCUS Trial to further quantify the benefit and optimize treatment strategies for these patients.
https://www.otcmarkets.com/stock/DCTH/news/Positive-Results-From-a-Multi-Center-Analysis-of-Delcath-PHP-Therapy-Published-in-Journal-of-Surgical-Oncology?id=179899
Delcath Announces Preliminary Safety Analysis for Phase 3 Focus Trial
“The DSMB’s recommendation to proceed without modification with the FOCUS Trial as planned confirms our own observations of the safety profile of PHP therapy based on prior research and our commercial experience with CHEMOSAT in Europe,” said Jennifer K. Simpson, Ph.D., MSN, CRNP President and CEO of Delcath. “Importantly, this initial independent evaluation of the safety profile of melphalan/HDS used the Generation Two filter configuration of the device and the current version of the procedure protocol, and so provides confidence in both our product and procedure. Given that safety concerns with the previous generation product and procedure were the primary issue in the FDA’s previous assessment, we are pleased to have successfully passed this important milestone.
http://delcath.com/reuters-news/?id=2323336
On Delcath’s 500th Commercial CHEMOSAT Treatment in Europe:
This is a meaningful milestone for Delcath, one that speaks to the belief physicians in Europe have developed in our product and this therapy for certain types of liver cancers. Our commercialization efforts in Europe have established a considerable body of published and presented research data that demonstrates the safety and efficacy of this therapy in appropriate patients. Further, Dutch Health Authorities recently included CHEMOSAT treatment in their published guidelines for ocular melanoma liver metastases, a step toward potential reimbursement coverage of CHEMOSAT in the Dutch market. We continue to leverage this experience to validate the safety and efficacy of the melphalan/Hepatic Delivery System (CHEMOSAT) in our clinical trials.”
http://delcath.com/reuters-news/?id=2330074